Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Rex Bionics PLC
  6. News
  7. Summary
    RXB   GB00BLRLQM66

REX BIONICS PLC

(RXB)
Delayed London Stock Exchange  -  02:29 2017-05-30 am EDT
1.750 GBX   -.--%
2017Rex Bionics : Results of General Meeting
PU
2017Rex Bionics : Funding and strategic review update
PU
2017Rex Bionics : initiates RAPPER III MS clinical trial
PU
SummaryChartsNewsCompanyFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Rex Bionics : Director Dealings

01/14/2015 | 11:40am EDT
Director Dealings Released : 22 December 2014

RNS Number : 3858A

Rex Bionics PLC

22 December 2014

Rex Bionics plc

("Rex Bionics" or the "Company")

Directors Dealings

22 December 2014 Rex Bionics plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users, announces that it has received notification on 19 December 2014 that the following directors of the Company have purchased ordinary shares of £1.00 each ("Ordinary Shares") in the Company on that date.

Name
Number of shares
Price
Crispin Simon, Chief Executive Officer
35,000
70.00p
Peter Worrall, Chief Financial Officer
14,000
70.00p

Following this purchase, they will have the following interests in Ordinary Shares.

Name
Total number of shares
Percentage of issued share capital
Crispin Simon, Chief Executive Officer
35,000
0.24%
Peter Worrall, Chief Financial Officer
19,556
0.14%

For further information please contact:

Rex Bionics Plc

Crispin Simon, Chief Executive Officer

+44 (0) 781 086 6386

Peter Worrall, Chief Financial Officer

+44 (0) 142 864 5416

Oriel Securities Limited (NOMAD and Broker)

Juliet Thompson/Jonathan Senior

+44 (0) 20 7710 7600

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Lindsey Neville

rexbionics@consilium-comms.com

+44 (0) 203 709 5700

About Rex Bionics plc

Rex Bionics (AIM: RXB) is the AIM-listed pioneer of the REX Robot that enhances the mobility of wheel-chair users. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics is working with physiotherapists to develop the practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists.

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep, cardiovascular performance, maintenance of joint range, and a reduction in common abdominal problems and prescription drug use. A programme of clinical trials is now under way to evaluate these potential benefits.

REX is used by people with complete spinal cord injury, as well as people who have suffered a stroke or other traumatic brain injury; and people with multiple sclerosis and muscular dystrophy. REX P, for use in the home, enables users to walk and stand with their hands free - providing more work and recreation options.

In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support growing demand for both REX products as well as developing the next generation of REX devices, REX 3.

REX is not approved for At-Home use in the United States of America.


This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSQKCDQDBDBCBD

distributed by

© Publicnow 2015
All news about REX BIONICS PLC
2017Rex Bionics : Results of General Meeting
PU
2017Rex Bionics : Funding and strategic review update
PU
2017Rex Bionics : initiates RAPPER III MS clinical trial
PU
2016Rex Bionics : Stroke & Brain Injury Clinical Trial in Australia
PU
2016Rex Bionics : Directors Interests
PU
2016Rex Bionics : Results of Annual General Meeting
PU
2016Rex Bionics : Retirement of Director
PU
2016Rex Bionics : Posting of Annual Report and Accounts
PU
2016Rex Bionics : Confirmation of Strategic Investment by Maxhealth
PU
2016Rex Bionics : Results of General Meeting
PU
More news
Chart REX BIONICS PLC
Duration : Period :
Rex Bionics PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
David John MacFarlene Executive Chairman
Susan Elizabeth Fraser Executive Director
Sector and Competitors
1st jan.Capi. (M$)
REX BIONICS PLC0.00%0
STRAUMANN HOLDING AG-52.59%14 916
SONOVA HOLDING AG-38.51%13 710
COCHLEAR LIMITED-9.99%8 244
DEMANT A/S-43.61%5 487
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.-7.43%2 877